Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT01482390
- Locations
- 🇺🇸
Carolina'S Center For Liver Disease, Statesville, North Carolina, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
🇺🇸Birmingham Gastro Associates, P.C., Birmingham, Alabama, United States
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT01480674
- Locations
- 🇫🇷
Ch De Brive La Gaillarde; Radiotherapie Oncologie, Brive La Gaillarde, France
🇫🇷Ch William Morey; Medecine 1, Chalon Sur Saone, France
🇫🇷Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, France
A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01476267
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Tocilizumab
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 608
- Registration Number
- NCT01474291
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT01474239
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
Phase 1
Completed
- Conditions
- Autistic Disorder
- Interventions
- Drug: RO5028442Drug: Placebo
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT01474278
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT01468077
A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: RO5503781
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT01462175
A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT01462162
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO5508887Drug: Placebo
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT01461967
© Copyright 2025. All Rights Reserved by MedPath